About: Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria
Creator	Rolain, Jean-Marc Peyclit, Lucie Alexandra Baron, Sophie Algaba, Rafael Antoniadou, Anastasia Tomas, Maria
Source	Medline; PMC
abstract	The emergence of new resistance mechanisms, the failure of classical antibiotics in clinic, the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases. Indeed, in recent years controversy has intensified over strains resistant to carbapenem and/or colistin. Various therapeutic solutions are used to overcome administration of last line antibiotics. In this context, drug repurposing, which consists of using a non-antibiotic compound to treat multi-drug resistant bacteria (MDR), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin-resistant bacteria with different studies describing repurposed compounds tested on Gram-negative bacteria. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat MDR bacterial infections and avoid therapeutic impasses.
has issue date	2019-06-11(xsd:dateTime)
bibo:doi	10.3389/fcimb.2019.00193
bibo:pmid	31245302
has license	cc-by
sha1sum (hex)	f64d07df542245c19781c36476a6cde273627f87
schema:url	https://doi.org/10.3389/fcimb.2019.00193
resource representing a document's title	Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria
has PubMed Central identifier	PMC6579884
has PubMed identifier	31245302
schema:publication	Front Cell Infect Microbiol
resource representing a document's body	covid:f64d07df542245c19781c36476a6cde273627f87#body_text
is schema:about of	named entity 'INFECTION' named entity 'DRUG COMBINATION' named entity 'BACTERIAL INFECTIONS' named entity 'CONCLUSION' named entity 'NON-' named entity 'COLISTIN' named entity 'ANTIBIOTIC' named entity 'MECHANISMS' named entity 'STRATEGIES' named entity 'ANTIBIOTICS' named entity 'STRAINS' named entity 'INDICATIONS' named entity 'COMPOUND' named entity 'TIME' named entity 'PHARMACEUTICAL INDUSTRIES' named entity 'CARBAPENEM' named entity 'CURRENT' named entity 'MICROBIOLOGY' named entity 'THINK' named entity 'ADMINISTRATION' named entity 'MAJOR' named entity 'CLINIC' named entity 'MAY HAVE' named entity 'HAVE' named entity 'CLINICIAN' named entity 'SERENDIPITY' named entity 'RECENT' named entity 'DESCRIBING' named entity 'UNCOMMON' named entity 'CHALLENGES' named entity 'OVERCOME' named entity 'DECREASE' named entity 'DISCUSS' named entity 'THESE' named entity 'TREATMENT' named entity 'BACTERIA.' named entity 'SECOND' named entity 'COMPUTATIONAL' named entity 'COLISTIN' named entity 'CARBAPENEM' named entity 'BACTERIA ' named entity 'MAIN' named entity 'FAILURE' named entity 'DRUGS' named entity 'FOCUS' named entity 'BIOLOGISTS' named entity 'INTEREST' named entity 'DRUG' named entity 'INDUSTRY' named entity 'STRATEGY' named entity 'SUCCESSFUL' named entity 'CONTEXT' named entity 'INCREASE' named entity 'JOURNAL ' named entity 'RESISTANT BACTERIA' named entity 'LACK' named entity 'REVIEW' named entity 'DRUG' named entity 'CELLULAR' named entity 'FIGHT' named entity 'TESTED' named entity 'MULTI' named entity 'TREAT' named entity 'REPORT' named entity 'GRAM-NEGATIVE BACTERIA' named entity 'NEW' named entity 'USING' named entity 'RESISTANT TO' named entity 'USED' named entity 'RESISTANT BACTERIA' named entity 'DESCRIBED' named entity 'WHAT' named entity 'INFECTIOUS DISEASES' named entity 'COMBINATION THERAPIES' named entity 'DRUG RESISTANT BACTERIA' named entity 'PROFITS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software